Cervical cancer

Lore & Background

Cervical cancer typically develops from precancerous changes over 10 to 20 years. About 75% of cervical cancers are squamous cell carcinomas, 20–25% are adenocarcinoma. Diagnosis is typically by cervical screening followed by a biopsy. Medical imaging is then done to determine whether or not the cancer has spread beyond the cervix. Early on, typically no symptoms are seen; later symptoms may include abnormal vaginal bleeding, pelvic pain or pain during sexual intercourse.

Reader's Guide

Cervical cancer is significant as a leading cause of cancer death among women globally, especially in low- and middle-income countries where almost 90% of cases and deaths occur. HPV vaccination is the most cost-effective public health measure against cervical cancer, with vaccines protecting against two to seven high-risk strains and potentially preventing up to 90% of cervical cancers. By the end of 2024, 147 countries provided the HPV vaccine in their national immunization schedule for girls. Cervical screening allows detection of pre-cancer, which can be treated to prevent development of cancer. Treatment may consist of some combination of surgery, chemotherapy, radiation therapy, and immunotherapy. The most famous immortalized cell line, HeLa, was developed from cervical cancer cells of Henrietta Lacks. 17 November is the Cervical Cancer Elimination Day of Action, marking the 2020 WHO launch of the Global strategy to accelerate elimination of cervical cancer as a public health problem.

Did You Know?

• Almost all cases (99%) of cervical cancer are linked to genital human papillomavirus infection (HPV).
• HPV vaccines may prevent up to 90% of cervical cancers.

The HPV Connection and Cellular Mechanism

Almost every case of cervical cancer—roughly 99%—traces back to a genital human papillomavirus infection. While over 200 HPV strains are known, only 12 are classified as high-risk, with types 16 and 18 alone responsible for three-quarters of global cases and types 31 and 45 accounting for another 10%. The underlying mechanism is remarkably specific: high-risk HPV can embed its genetic material directly into the host cell's DNA, triggering production of two viral proteins, E6 and E7. E6 dismantles p53, a critical tumor-suppressing protein, while E7 degrades pRb, another guardian of cell-cycle regulation. With both safeguards destroyed, cells lose their ability to control division, blood vessels proliferate to feed the growing mass, and unchecked cellular replication takes hold. Most people who contract HPV never develop cancer, but co-infections like HIV or trichomoniasis, combined with immunosuppressive conditions or medications, make it far harder for the body to clear the virus. Smoking compounds the danger, roughly doubling or tripling invasive cancer risk among HPV-positive individuals, and passive exposure also contributes to elevated risk.

The Long Silent Progression and Detection

Cervical cancer is notorious for its stealth. In its earliest stages, it typically produces no symptoms whatsoever, giving the disease a quiet window of 10 to 20 years as precancerous cellular changes slowly accumulate before becoming invasive. When symptoms finally emerge, they can be easily overlooked: unusual vaginal bleeding, pain during intercourse, or a persistent discharge. Bleeding after sex, between periods, or after menopause are particularly telling signs, though they may also stem from benign causes. In advanced disease, the picture darkens considerably—metastases may appear in the abdomen or lungs, and locally invasive tumors can block urinary flow, causing kidney enlargement and flank pain, obstruct pelvic veins producing leg swelling and blood clots, or erode into the rectum. Diagnosis usually begins with a cervical screening test, followed by a biopsy to confirm malignancy. Medical imaging then maps whether the cancer has breached the cervix. About 75% of confirmed cases are squamous cell carcinomas, while 20 to 25% are adenocarcinomas, each linked to different HPV subtypes.

Prevention, Vaccination, and Treatment

The HPV vaccine stands as the single most cost-effective public health intervention against cervical cancer. By targeting between two and seven high-risk viral strains, these vaccines can avert up to 90% of cases. By late 2024, 147 countries had incorporated the vaccine into their national immunization schedules for girls, and 47 had extended coverage to boys as well. Because no vaccine covers every strain, guidelines still call for regular cervical screening, which can catch precancerous changes before they become malignant and allow for curative treatment. When cancer is confirmed, treatment typically blends surgery, chemotherapy, radiation, and increasingly immunotherapy. Five-year survival in the United States hovers around 69%, though this figure swings dramatically depending on how early the disease is caught. In developed nations, decades of widespread screening programs have already driven cervical cancer rates down sharply, demonstrating that a combination of vaccination and vigilant screening can fundamentally reshape the disease's trajectory.

Global Burden and Enduring Legacy

Cervical cancer ranks as the fourth most common cancer and the fourth leading cause of cancer death among women worldwide. In 2022 alone, more than 660,000 new cases were diagnosed and approximately 350,000 women lost their lives, accounting for roughly 8% of all cancer cases and deaths. The burden is profoundly unequal: nearly 90% of cases and deaths cluster in low- and middle-income countries, where cervical cancer represents 17% of all female cancer diagnoses, compared to just 2% in high-income nations. This stark divide underscores how access to screening and vaccination shapes outcomes. Beyond epidemiology, cervical cancer left an indelible mark on medical science through HeLa, the most famous immortalized cell line in history, derived from the cervical cancer cells of Henrietta Lacks. In 2020, the World Health Organization launched a global strategy to eliminate cervical cancer as a public health problem, a resolution endorsed by 194 countries. November 17 is now observed as Cervical Cancer Elimination Day of Action, marking that pivotal commitment.